Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Quarterly Analysis

Owen Stevens
June 2, 2017

Neurocrine Biosciences Inc now has $3.60 billion valuation. It has underperformed by 4.19% the S&P500.

Paloma Partners Management Company increased Ralph Lauren Corp (RL) stake by 101.9% reported in 2016Q4 SEC filing. The Paloma Partners Management Company holds 16,152 shares with $1.46 million value, up from 8,000 last quarter. First Mercantile Trust Co. now owns 3,082 shares of the company's stock valued at $133,000 after buying an additional 560 shares in the last quarter. Boeing Co now has $113.61B valuation. It has outperformed by 24.43% the S&P500.

NBIX has been the topic of a number of other research reports. 963 shares valued at $41,544 were sold by Bozigian Haig P. on Monday, February 6. Volume on the day was 2.06 million shares. The insider Gangestad Nicholas C sold $523,613. The company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by $0.23. For the outlook of the current financial quarter, Analysts think the firm will post 0.08 earnings per share. PCH's profit will be $12.98 million for 35.23 P/E if the $0.32 EPS becomes a reality. It also upped Vanguard Ftse All (VEU) stake by 7,862 shares and now owns 43,011 shares.

The consensus recommendation - averaging the work of 39 analysts - of 2 for Schlumberger Limited (NYSE:SLB) points to moderate case.

Several analysts recently issued reports on the company. (NASDAQ:NBIX). Nomura holds 9,031 shares. Regentatlantic Capital Limited Liability Company holds 0.03% or 3,050 shares. Credit Suisse upgraded the stock to "Outperform" rating in Friday, September 25 report. Canaccord Genuity has "Buy" rating and $150 target. As per Thursday, January 21, the company rating was initiated by Citigroup. The firm has "Neutral" rating by JP Morgan given on Wednesday, December 14. The company has market cap of $5.52 million. As per Friday, April 28, the company rating was maintained by Credit Suisse. Oracle Inv Mgmt holds 1.14% or 1.49M shares. The Company's year to date (YTD) performance is now positive at 12.45%.

Investors sentiment increased to 1.15 in 2016 Q4. Its up 0.08, from 0.78 in 2016Q3. It increased, as 67 investors sold MMM shares while 592 reduced holdings. 137 funds opened positions while 378 raised stakes. 383.70 million shares or 2.52% more from 374.26 million shares in 2016Q3 were reported. About 1.41M shares traded or 1.44% up from the average. Citigroup Incorporated holds 0.01% or 167,853 shares in its portfolio. First Retail Bank Trust accumulated 0.2% or 1,490 shares. Prentiss Smith Inc reported 220 shares.

Institutional investors have recently bought and sold shares of the stock. Inverness Counsel Limited Company Ny stated it has 12,771 shares. Todd Asset Mgmt Lc has invested 0.04% in Procter & Gamble Co (NYSE:PG). Pacific Glob Investment Company accumulated 0.82% or 22,511 shares. It also reduced Alexion Pharmaceuticals Inc (NASDAQ:ALXN) stake by 50,000 shares and now owns 200,000 shares. DragonWave, Inc.(USA) (NASDAQ:DRWI) has declined 77.66% since May 30, 2016 and is downtrending. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and sixteen have assigned a buy rating to the stock. Therefore 100% are positive. Boeing had 38 analyst reports since August 26, 2015 according to SRatingsIntel.

The collective rating of 1.6 for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) versus those who think you should sell it. The rating was maintained by Piper Jaffray with "Overweight" on Thursday, October 8. Nationwide Fund Advisors owned 0.15% of Neurocrine Biosciences worth $5,483,000 at the end of the most recent quarter. The firm has "Buy" rating by Needham given on Tuesday, October 18. Finally, JPMorgan Chase & Co. set a $57.00 price target on Neurocrine Biosciences and gave the company a "buy" rating in a report on Wednesday, May 24th. (NASDAQ:NBIX) on Tuesday, November 22 with "Perform" rating. Deutsche Bank initiated Neurocrine Biosciences, Inc. (NASDAQ:NBIX) on Monday, October 12 with "Outperform" rating. BMO Capital started coverage with an initial rating of "Outperform". Bnp Paribas Arbitrage Sa owns 12,775 shares or 0% of their United States portfolio. $152,438 worth of Neurocrine Biosciences, Inc. For annual bases, the firm attains $1.47 per-share earnings for FY 2016 trends against $1.72 for fiscal year 2017 Trends, views extracted from WSJ. Grigoriadis Dimitri E. sold 10,000 shares worth $550,000. 1,750 shares were sold by Coughlin Timothy P, worth $75,898. $66,024 worth of Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) kept in active run as it closed at $43.50 by slightly down -0.05% with session volume was recorded 855668. (NASDAQ:NBIX). Ibm Retirement Fund has 6,892 shares for 0.01% of their portfolio.

Investors sentiment decreased to 1.06 in Q4 2016.

Other reports by VgToday

Discuss This Article